Impaired balance between neutrophil extracellular trap formation and degradation by DNases in COVID-19 disease
Background Thrombo-inflammation and neutrophil extracellular traps (NETs) are exacerbated in severe cases of COVID-19, potentially contributing to disease exacerbation. However, the mechanisms underpinning this dysregulation remain elusive. We hypothesised that lower DNase activity may be associated...
Uložené v:
| Vydané v: | Journal of translational medicine Ročník 22; číslo 1; s. 246 - 18 |
|---|---|
| Hlavní autori: | , , , , , , , , , , , , , |
| Médium: | Journal Article |
| Jazyk: | English |
| Vydavateľské údaje: |
London
BioMed Central
07.03.2024
BioMed Central Ltd Springer Nature B.V BMC |
| Predmet: | |
| ISSN: | 1479-5876, 1479-5876 |
| On-line prístup: | Získať plný text |
| Tagy: |
Pridať tag
Žiadne tagy, Buďte prvý, kto otaguje tento záznam!
|
| Abstract | Background
Thrombo-inflammation and neutrophil extracellular traps (NETs) are exacerbated in severe cases of COVID-19, potentially contributing to disease exacerbation. However, the mechanisms underpinning this dysregulation remain elusive. We hypothesised that lower DNase activity may be associated with higher NETosis and clinical worsening in patients with COVID-19.
Methods
Biological samples were obtained from hospitalized patients (15 severe, 37 critical at sampling) and 93 non-severe ambulatory cases. Our aims were to compare NET biomarkers, functional DNase levels, and explore mechanisms driving any imbalance concerning disease severity.
Results
Functional DNase levels were diminished in the most severe patients, paralleling an imbalance between NET markers and DNase activity. DNase1 antigen levels were higher in ambulatory cases but lower in severe patients. DNase1L3 antigen levels remained consistent across subgroups, not rising alongside NET markers.
DNASE1
polymorphisms correlated with reduced DNase1 antigen levels. Moreover, a quantitative deficiency in plasmacytoid dendritic cells (pDCs), which primarily express
DNase1L3
, was observed in critical patients. Analysis of public single-cell RNAseq data revealed reduced
DNase1L3
expression in pDCs from severe COVID-19 patient.
Conclusion
Severe and critical COVID-19 cases exhibited an imbalance between NET and DNase functional activity and quantity. Early identification of NETosis imbalance could guide targeted therapies against thrombo-inflammation in COVID-19-related sepsis, such as DNase administration, to avert clinical deterioration.
Trial registration
: COVERAGE trial (NCT04356495) and COLCOV19-BX study (NCT04332016).
Graphical Abstract |
|---|---|
| AbstractList | Thrombo-inflammation and neutrophil extracellular traps (NETs) are exacerbated in severe cases of COVID-19, potentially contributing to disease exacerbation. However, the mechanisms underpinning this dysregulation remain elusive. We hypothesised that lower DNase activity may be associated with higher NETosis and clinical worsening in patients with COVID-19.
Biological samples were obtained from hospitalized patients (15 severe, 37 critical at sampling) and 93 non-severe ambulatory cases. Our aims were to compare NET biomarkers, functional DNase levels, and explore mechanisms driving any imbalance concerning disease severity.
Functional DNase levels were diminished in the most severe patients, paralleling an imbalance between NET markers and DNase activity. DNase1 antigen levels were higher in ambulatory cases but lower in severe patients. DNase1L3 antigen levels remained consistent across subgroups, not rising alongside NET markers. DNASE1 polymorphisms correlated with reduced DNase1 antigen levels. Moreover, a quantitative deficiency in plasmacytoid dendritic cells (pDCs), which primarily express DNase1L3, was observed in critical patients. Analysis of public single-cell RNAseq data revealed reduced DNase1L3 expression in pDCs from severe COVID-19 patient.
Severe and critical COVID-19 cases exhibited an imbalance between NET and DNase functional activity and quantity. Early identification of NETosis imbalance could guide targeted therapies against thrombo-inflammation in COVID-19-related sepsis, such as DNase administration, to avert clinical deterioration.
COVERAGE trial (NCT04356495) and COLCOV19-BX study (NCT04332016). Abstract Background Thrombo-inflammation and neutrophil extracellular traps (NETs) are exacerbated in severe cases of COVID-19, potentially contributing to disease exacerbation. However, the mechanisms underpinning this dysregulation remain elusive. We hypothesised that lower DNase activity may be associated with higher NETosis and clinical worsening in patients with COVID-19. Methods Biological samples were obtained from hospitalized patients (15 severe, 37 critical at sampling) and 93 non-severe ambulatory cases. Our aims were to compare NET biomarkers, functional DNase levels, and explore mechanisms driving any imbalance concerning disease severity. Results Functional DNase levels were diminished in the most severe patients, paralleling an imbalance between NET markers and DNase activity. DNase1 antigen levels were higher in ambulatory cases but lower in severe patients. DNase1L3 antigen levels remained consistent across subgroups, not rising alongside NET markers. DNASE1 polymorphisms correlated with reduced DNase1 antigen levels. Moreover, a quantitative deficiency in plasmacytoid dendritic cells (pDCs), which primarily express DNase1L3, was observed in critical patients. Analysis of public single-cell RNAseq data revealed reduced DNase1L3 expression in pDCs from severe COVID-19 patient. Conclusion Severe and critical COVID-19 cases exhibited an imbalance between NET and DNase functional activity and quantity. Early identification of NETosis imbalance could guide targeted therapies against thrombo-inflammation in COVID-19-related sepsis, such as DNase administration, to avert clinical deterioration. Trial registration: COVERAGE trial (NCT04356495) and COLCOV19-BX study (NCT04332016). Graphical Abstract Background Thrombo-inflammation and neutrophil extracellular traps (NETs) are exacerbated in severe cases of COVID-19, potentially contributing to disease exacerbation. However, the mechanisms underpinning this dysregulation remain elusive. We hypothesised that lower DNase activity may be associated with higher NETosis and clinical worsening in patients with COVID-19. Methods Biological samples were obtained from hospitalized patients (15 severe, 37 critical at sampling) and 93 non-severe ambulatory cases. Our aims were to compare NET biomarkers, functional DNase levels, and explore mechanisms driving any imbalance concerning disease severity. Results Functional DNase levels were diminished in the most severe patients, paralleling an imbalance between NET markers and DNase activity. DNase1 antigen levels were higher in ambulatory cases but lower in severe patients. DNase1L3 antigen levels remained consistent across subgroups, not rising alongside NET markers. DNASE1 polymorphisms correlated with reduced DNase1 antigen levels. Moreover, a quantitative deficiency in plasmacytoid dendritic cells (pDCs), which primarily express DNase1L3, was observed in critical patients. Analysis of public single-cell RNAseq data revealed reduced DNase1L3 expression in pDCs from severe COVID-19 patient. Conclusion Severe and critical COVID-19 cases exhibited an imbalance between NET and DNase functional activity and quantity. Early identification of NETosis imbalance could guide targeted therapies against thrombo-inflammation in COVID-19-related sepsis, such as DNase administration, to avert clinical deterioration. Trial registration: COVERAGE trial (NCT04356495) and COLCOV19-BX study (NCT04332016). Graphical Background: Thrombo-inflammation and neutrophil extracellular traps (NETs) are exacerbated in severe cases of COVID-19, potentially contributing to disease exacerbation. However, the mechanisms underpinning this dysregulation remain elusive. We hypothesised that lower DNase activity may be associated with higher NETosis and clinical worsening in patients with COVID-19.Methods: Biological samples were obtained from hospitalized patients (15 severe, 37 critical at sampling) and 93 non-severe ambulatory cases. Our aims were to compare NET biomarkers, functional DNase levels, and explore mechanisms driving any imbalance concerning disease severity.Results: Functional DNase levels were diminished in the most severe patients, paralleling an imbalance between NET markers and DNase activity. DNase1 antigen levels were higher in ambulatory cases but lower in severe patients. DNase1L3 antigen levels remained consistent across subgroups, not rising alongside NET markers. DNASE1 polymorphisms correlated with reduced DNase1 antigen levels. Moreover, a quantitative deficiency in plasmacytoid dendritic cells (pDCs), which primarily express DNase1L3, was observed in critical patients. Analysis of public single-cell RNAseq data revealed reduced DNase1L3 expression in pDCs from severe COVID-19 patient.ConclusionSevere and critical COVID-19 cases exhibited an imbalance between NET and DNase functional activity and quantity. Early identification of NETosis imbalance could guide targeted therapies against thrombo-inflammation in COVID-19-related sepsis, such as DNase administration, to avert clinical deterioration.Trial registration: COVERAGE trial (NCT04356495) and COLCOV19-BX study (NCT04332016).Conclusion: Severe and critical COVID-19 cases exhibited an imbalance between NET and DNase functional activity and quantity. Early identification of NETosis imbalance could guide targeted therapies against thrombo-inflammation in COVID-19-related sepsis, such as DNase administration, to avert clinical deterioration.Trial registration: COVERAGE trial (NCT04356495) and COLCOV19-BX study (NCT04332016). BackgroundThrombo-inflammation and neutrophil extracellular traps (NETs) are exacerbated in severe cases of COVID-19, potentially contributing to disease exacerbation. However, the mechanisms underpinning this dysregulation remain elusive. We hypothesised that lower DNase activity may be associated with higher NETosis and clinical worsening in patients with COVID-19.MethodsBiological samples were obtained from hospitalized patients (15 severe, 37 critical at sampling) and 93 non-severe ambulatory cases. Our aims were to compare NET biomarkers, functional DNase levels, and explore mechanisms driving any imbalance concerning disease severity.ResultsFunctional DNase levels were diminished in the most severe patients, paralleling an imbalance between NET markers and DNase activity. DNase1 antigen levels were higher in ambulatory cases but lower in severe patients. DNase1L3 antigen levels remained consistent across subgroups, not rising alongside NET markers. DNASE1 polymorphisms correlated with reduced DNase1 antigen levels. Moreover, a quantitative deficiency in plasmacytoid dendritic cells (pDCs), which primarily express DNase1L3, was observed in critical patients. Analysis of public single-cell RNAseq data revealed reduced DNase1L3 expression in pDCs from severe COVID-19 patient.ConclusionSevere and critical COVID-19 cases exhibited an imbalance between NET and DNase functional activity and quantity. Early identification of NETosis imbalance could guide targeted therapies against thrombo-inflammation in COVID-19-related sepsis, such as DNase administration, to avert clinical deterioration.Trial registration: COVERAGE trial (NCT04356495) and COLCOV19-BX study (NCT04332016). Background Thrombo-inflammation and neutrophil extracellular traps (NETs) are exacerbated in severe cases of COVID-19, potentially contributing to disease exacerbation. However, the mechanisms underpinning this dysregulation remain elusive. We hypothesised that lower DNase activity may be associated with higher NETosis and clinical worsening in patients with COVID-19. Methods Biological samples were obtained from hospitalized patients (15 severe, 37 critical at sampling) and 93 non-severe ambulatory cases. Our aims were to compare NET biomarkers, functional DNase levels, and explore mechanisms driving any imbalance concerning disease severity. Results Functional DNase levels were diminished in the most severe patients, paralleling an imbalance between NET markers and DNase activity. DNase1 antigen levels were higher in ambulatory cases but lower in severe patients. DNase1L3 antigen levels remained consistent across subgroups, not rising alongside NET markers. DNASE1 polymorphisms correlated with reduced DNase1 antigen levels. Moreover, a quantitative deficiency in plasmacytoid dendritic cells (pDCs), which primarily express DNase1L3 , was observed in critical patients. Analysis of public single-cell RNAseq data revealed reduced DNase1L3 expression in pDCs from severe COVID-19 patient. Conclusion Severe and critical COVID-19 cases exhibited an imbalance between NET and DNase functional activity and quantity. Early identification of NETosis imbalance could guide targeted therapies against thrombo-inflammation in COVID-19-related sepsis, such as DNase administration, to avert clinical deterioration. Trial registration : COVERAGE trial (NCT04356495) and COLCOV19-BX study (NCT04332016). Graphical Abstract Thrombo-inflammation and neutrophil extracellular traps (NETs) are exacerbated in severe cases of COVID-19, potentially contributing to disease exacerbation. However, the mechanisms underpinning this dysregulation remain elusive. We hypothesised that lower DNase activity may be associated with higher NETosis and clinical worsening in patients with COVID-19.BACKGROUNDThrombo-inflammation and neutrophil extracellular traps (NETs) are exacerbated in severe cases of COVID-19, potentially contributing to disease exacerbation. However, the mechanisms underpinning this dysregulation remain elusive. We hypothesised that lower DNase activity may be associated with higher NETosis and clinical worsening in patients with COVID-19.Biological samples were obtained from hospitalized patients (15 severe, 37 critical at sampling) and 93 non-severe ambulatory cases. Our aims were to compare NET biomarkers, functional DNase levels, and explore mechanisms driving any imbalance concerning disease severity.METHODSBiological samples were obtained from hospitalized patients (15 severe, 37 critical at sampling) and 93 non-severe ambulatory cases. Our aims were to compare NET biomarkers, functional DNase levels, and explore mechanisms driving any imbalance concerning disease severity.Functional DNase levels were diminished in the most severe patients, paralleling an imbalance between NET markers and DNase activity. DNase1 antigen levels were higher in ambulatory cases but lower in severe patients. DNase1L3 antigen levels remained consistent across subgroups, not rising alongside NET markers. DNASE1 polymorphisms correlated with reduced DNase1 antigen levels. Moreover, a quantitative deficiency in plasmacytoid dendritic cells (pDCs), which primarily express DNase1L3, was observed in critical patients. Analysis of public single-cell RNAseq data revealed reduced DNase1L3 expression in pDCs from severe COVID-19 patient.RESULTSFunctional DNase levels were diminished in the most severe patients, paralleling an imbalance between NET markers and DNase activity. DNase1 antigen levels were higher in ambulatory cases but lower in severe patients. DNase1L3 antigen levels remained consistent across subgroups, not rising alongside NET markers. DNASE1 polymorphisms correlated with reduced DNase1 antigen levels. Moreover, a quantitative deficiency in plasmacytoid dendritic cells (pDCs), which primarily express DNase1L3, was observed in critical patients. Analysis of public single-cell RNAseq data revealed reduced DNase1L3 expression in pDCs from severe COVID-19 patient.Severe and critical COVID-19 cases exhibited an imbalance between NET and DNase functional activity and quantity. Early identification of NETosis imbalance could guide targeted therapies against thrombo-inflammation in COVID-19-related sepsis, such as DNase administration, to avert clinical deterioration.CONCLUSIONSevere and critical COVID-19 cases exhibited an imbalance between NET and DNase functional activity and quantity. Early identification of NETosis imbalance could guide targeted therapies against thrombo-inflammation in COVID-19-related sepsis, such as DNase administration, to avert clinical deterioration.COVERAGE trial (NCT04356495) and COLCOV19-BX study (NCT04332016).TRIAL REGISTRATIONCOVERAGE trial (NCT04356495) and COLCOV19-BX study (NCT04332016). Thrombo-inflammation and neutrophil extracellular traps (NETs) are exacerbated in severe cases of COVID-19, potentially contributing to disease exacerbation. However, the mechanisms underpinning this dysregulation remain elusive. We hypothesised that lower DNase activity may be associated with higher NETosis and clinical worsening in patients with COVID-19. Biological samples were obtained from hospitalized patients (15 severe, 37 critical at sampling) and 93 non-severe ambulatory cases. Our aims were to compare NET biomarkers, functional DNase levels, and explore mechanisms driving any imbalance concerning disease severity. Functional DNase levels were diminished in the most severe patients, paralleling an imbalance between NET markers and DNase activity. DNase1 antigen levels were higher in ambulatory cases but lower in severe patients. DNase1L3 antigen levels remained consistent across subgroups, not rising alongside NET markers. DNASE1 polymorphisms correlated with reduced DNase1 antigen levels. Moreover, a quantitative deficiency in plasmacytoid dendritic cells (pDCs), which primarily express DNase1L3, was observed in critical patients. Analysis of public single-cell RNAseq data revealed reduced DNase1L3 expression in pDCs from severe COVID-19 patient. Severe and critical COVID-19 cases exhibited an imbalance between NET and DNase functional activity and quantity. Early identification of NETosis imbalance could guide targeted therapies against thrombo-inflammation in COVID-19-related sepsis, such as DNase administration, to avert clinical deterioration. |
| ArticleNumber | 246 |
| Audience | Academic |
| Author | Clequin, Etienne Dussiau, Charles Goret, Julien Zouine, Atika Malvy, Denis Pellegrin, Isabelle Prevel, Renaud Labrouche-Colomer, Sylvie Garcia, Geoffrey Mamani-Matsuda, Maria Trégouët, David-Alexandre Dewitte, Antoine Duvignaud, Alexandre James, Chloe |
| Author_xml | – sequence: 1 givenname: Geoffrey surname: Garcia fullname: Garcia, Geoffrey organization: Biology of Cardiovascular Disease, INSERM, UMR 1034, Bordeaux University, CHU Haut-Lévêque – sequence: 2 givenname: Sylvie surname: Labrouche-Colomer fullname: Labrouche-Colomer, Sylvie organization: Biology of Cardiovascular Disease, INSERM, UMR 1034, Bordeaux University, CHU Haut-Lévêque, Laboratory of Hematology, Bordeaux University Hospital – sequence: 3 givenname: Alexandre surname: Duvignaud fullname: Duvignaud, Alexandre organization: Department of Infectious Diseases and Tropical Medicine, Hôpital Pellegrin, CHU Bordeaux, University Bordeaux, INSERM, Bordeaux Population Health Research Center, UMR 1219 – sequence: 4 givenname: Etienne surname: Clequin fullname: Clequin, Etienne organization: CNRS, ImmunoConcEpT, UMR 5164, Inserm ERL1303, Bordeaux University, Department of Anaesthesia and Intensive Care, Bordeaux University Hospital – sequence: 5 givenname: Charles surname: Dussiau fullname: Dussiau, Charles organization: Biology of Cardiovascular Disease, INSERM, UMR 1034, Bordeaux University, CHU Haut-Lévêque, Laboratory of Hematology, Bordeaux University Hospital – sequence: 6 givenname: David-Alexandre surname: Trégouët fullname: Trégouët, David-Alexandre organization: University Bordeaux, INSERM, Bordeaux Population Health Research Center, UMR 1219 – sequence: 7 givenname: Denis surname: Malvy fullname: Malvy, Denis organization: Department of Infectious Diseases and Tropical Medicine, Hôpital Pellegrin, CHU Bordeaux, University Bordeaux, INSERM, Bordeaux Population Health Research Center, UMR 1219 – sequence: 8 givenname: Renaud surname: Prevel fullname: Prevel, Renaud organization: Medical Intensive Care Unit, Bordeaux University Hospital, Centre de Recherche Cardio-Thoracique de Bordeaux, INSERM, UMR 1045, Bordeaux University – sequence: 9 givenname: Atika surname: Zouine fullname: Zouine, Atika organization: CNRS, INSERM, TBM-Core, US5, UAR 3427, Flow Cytometry Facility, Bordeaux University – sequence: 10 givenname: Isabelle surname: Pellegrin fullname: Pellegrin, Isabelle organization: CNRS, ImmunoConcEpT, UMR 5164, Inserm ERL1303, Bordeaux University, Centre de Ressources Biologiques, Bordeaux University Hospital – sequence: 11 givenname: Julien surname: Goret fullname: Goret, Julien organization: CNRS, ImmunoConcEpT, UMR 5164, Inserm ERL1303, Bordeaux University, Department of Immunology and Immunogenetics, Bordeaux University Hospital – sequence: 12 givenname: Maria surname: Mamani-Matsuda fullname: Mamani-Matsuda, Maria organization: CNRS, ImmunoConcEpT, UMR 5164, Inserm ERL1303, Bordeaux University – sequence: 13 givenname: Antoine orcidid: 0000-0003-1112-4845 surname: Dewitte fullname: Dewitte, Antoine organization: CNRS, ImmunoConcEpT, UMR 5164, Inserm ERL1303, Bordeaux University, Department of Anaesthesia and Intensive Care, Bordeaux University Hospital – sequence: 14 givenname: Chloe surname: James fullname: James, Chloe email: chloe.james@inserm.fr organization: Biology of Cardiovascular Disease, INSERM, UMR 1034, Bordeaux University, CHU Haut-Lévêque, Laboratory of Hematology, Bordeaux University Hospital |
| BackLink | https://www.ncbi.nlm.nih.gov/pubmed/38454482$$D View this record in MEDLINE/PubMed https://hal.science/hal-04567306$$DView record in HAL |
| BookMark | eNp9Uk1v1DAUjFAR_YA_wAFF4lIOKbZjx_YJrVqgK1X0AlwtO37eusrai50t9N_jNC39EKp8yMvLzLy88exXOyEGqKq3GB1hLLqPGRPZ8QYR2iCGKG34i2oPUy4bJni386DerfZzvkQFyah8Ve22ohRUkL0qLNcb7RPY2uhBhx5qA-NvgFAH2I4pbi78UMOfMekehmE76FSXelO7mNZ69DHUOtjawippO7-b6_rkm86Qax_q4_Ofy5MGy9r6DKX5unrp9JDhze3zoPrx5fP349Pm7Pzr8nhx1vQdJWPjhAXjWAu0x0A0WClYx0UrdC-Z7FrtsG0tIZJg46BjVnQOaegQNhYxg9uDajnr2qgv1Sb5tU7XKmqvbhoxrZROo-8HUNIwbol1tO8xNU4bSsBZ2xuGsZFs0vo0a222Zg22h1AcGB6JPv4S_IVaxSuFkcQSEVkUPswKF094p4szNfUQLeu1qLuaph3eTkvx1xbyqNY-T97rAHGbFZGMco5oceGgev8Eehm3KRRfJ1QnRIs4v0etdNnWBxeny5xE1YILxhlvaVtQR_9BlWNh7fuSO-dL_xHh3UNX_q11F60CEDOgTzHnBE71fryJSFH2Q3FHTSlWc4pVyaa6SbGafpk8od6pP0tqZ1Iu4LCCdO_GM6y_VmsDew |
| CitedBy_id | crossref_primary_10_1371_journal_pone_0321094 crossref_primary_10_1038_s41598_025_95122_7 crossref_primary_10_3390_ijms26157464 crossref_primary_10_3389_fimmu_2025_1530753 crossref_primary_10_1002_iid3_1343 crossref_primary_10_31083_j_fbl2907244 crossref_primary_10_1038_s41556_025_01671_4 crossref_primary_10_3389_fimmu_2025_1507167 crossref_primary_10_3390_jcm14176011 crossref_primary_10_1016_j_jtha_2024_11_028 crossref_primary_10_1038_s41392_025_02174_2 |
| Cites_doi | 10.1097/00003246-198411000-00012 10.1007/s11222-012-9343-7 10.1126/science.1092385 10.1016/j.cca.2016.05.029 10.1111/jth.15003 10.1172/jci.insight.150111 10.1016/j.immuni.2022.11.007 10.1371/journal.ppat.1009878 10.1126/sciadv.abc1518 10.1111/imm.13254 10.1038/s41591-020-1038-6 10.1038/s41556-021-00681-2 10.1038/s41577-021-00536-9 10.1056/NEJMoa2001017 10.1007/BF01709751 10.1016/j.cell.2016.05.034 10.1172/JCI140335 10.1186/s12931-023-02336-2 10.1001/jama.2016.0287 10.1001/jama.2012.5669 10.1038/s41591-021-01329-2 10.1002/cyto.a.24269 10.1164/rccm.201803-0589OC 10.1186/s13073-023-01173-8 10.1186/s13063-020-04619-1 10.1016/S1473-3099(20)30484-9 10.1001/jamainternmed.2020.0994 10.1172/jci.insight.160332 10.1016/S2213-2600(20)30316-7 10.3389/fimmu.2021.714833 10.1186/s12871-019-0911-7 10.1038/nri3345 10.1038/s41579-022-00713-0 10.1016/j.immuni.2020.07.026 10.1016/j.jtha.2023.02.033 10.3389/fimmu.2022.851497 10.1136/bmjopen-2020-043790 10.1161/ATVBAHA.119.312463 10.3389/fimmu.2023.1181761 10.1001/jama.2020.12839 10.1042/bj20040046 10.1002/iid3.402 10.1161/CIRCRESAHA.120.317447 10.1016/j.cmi.2022.02.031 10.1126/science.abd4585 10.1097/SHK.0000000000001804 10.1111/j.1742-4658.2008.06849.x 10.1007/s12026-017-8905-3 10.1126/science.aam8897 |
| ContentType | Journal Article |
| Copyright | The Author(s) 2024 2024. The Author(s). COPYRIGHT 2024 BioMed Central Ltd. 2024. This work is licensed under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. licence_http://creativecommons.org/publicdomain/zero |
| Copyright_xml | – notice: The Author(s) 2024 – notice: 2024. The Author(s). – notice: COPYRIGHT 2024 BioMed Central Ltd. – notice: 2024. This work is licensed under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. – notice: licence_http://creativecommons.org/publicdomain/zero |
| DBID | C6C AAYXX CITATION NPM 3V. 7T5 7X7 7XB 88E 8FI 8FJ 8FK ABUWG AFKRA AZQEC BENPR CCPQU COVID DWQXO FYUFA GHDGH H94 K9. M0S M1P PHGZM PHGZT PIMPY PJZUB PKEHL PPXIY PQEST PQQKQ PQUKI PRINS 7X8 1XC VOOES 5PM DOA |
| DOI | 10.1186/s12967-024-05044-7 |
| DatabaseName | Springer Nature OA Free Journals CrossRef PubMed ProQuest Central (Corporate) Immunology Abstracts Health & Medical Collection (Proquest) ProQuest Central (purchase pre-March 2016) Medical Database (Alumni Edition) Hospital Premium Collection Hospital Premium Collection (Alumni Edition) ProQuest Central (Alumni) (purchase pre-March 2016) ProQuest Central (Alumni) ProQuest Central ProQuest Central Essentials ProQuest Central ProQuest One Coronavirus Research Database ProQuest Central Health Research Premium Collection Health Research Premium Collection (Alumni) AIDS and Cancer Research Abstracts ProQuest Health & Medical Complete (Alumni) ProQuest Health & Medical Collection PML(ProQuest Medical Library) ProQuest Central Premium ProQuest One Academic Publicly Available Content Database (Proquest) ProQuest Health & Medical Research Collection ProQuest One Academic Middle East (New) ProQuest One Health & Nursing ProQuest One Academic Eastern Edition (DO NOT USE) ProQuest One Academic (retired) ProQuest One Academic UKI Edition ProQuest Central China MEDLINE - Academic Hyper Article en Ligne (HAL) Hyper Article en Ligne (HAL) (Open Access) PubMed Central (Full Participant titles) Openly Available Collection - DOAJ |
| DatabaseTitle | CrossRef PubMed Publicly Available Content Database ProQuest One Academic Middle East (New) ProQuest Central Essentials ProQuest Health & Medical Complete (Alumni) ProQuest Central (Alumni Edition) ProQuest One Community College ProQuest One Health & Nursing ProQuest Central China ProQuest Central ProQuest Health & Medical Research Collection Health Research Premium Collection Health and Medicine Complete (Alumni Edition) ProQuest Central Korea Health & Medical Research Collection AIDS and Cancer Research Abstracts ProQuest Central (New) ProQuest Medical Library (Alumni) ProQuest One Academic Eastern Edition Coronavirus Research Database ProQuest Hospital Collection Health Research Premium Collection (Alumni) ProQuest Hospital Collection (Alumni) ProQuest Health & Medical Complete ProQuest Medical Library ProQuest One Academic UKI Edition Immunology Abstracts ProQuest One Academic ProQuest One Academic (New) ProQuest Central (Alumni) MEDLINE - Academic |
| DatabaseTitleList | PubMed Publicly Available Content Database MEDLINE - Academic |
| Database_xml | – sequence: 1 dbid: DOA name: DOAJ Directory of Open Access Journals url: https://www.doaj.org/ sourceTypes: Open Website – sequence: 2 dbid: NPM name: PubMed url: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 3 dbid: PIMPY name: Publicly Available Content Database (Proquest) url: http://search.proquest.com/publiccontent sourceTypes: Aggregation Database |
| DeliveryMethod | fulltext_linktorsrc |
| Discipline | Medicine |
| EISSN | 1479-5876 |
| EndPage | 18 |
| ExternalDocumentID | oai_doaj_org_article_9b57d2df4cc14bfab42efddcb511b951 PMC10919029 oai:HAL:hal-04567306v1 A785757343 38454482 10_1186_s12967_024_05044_7 |
| Genre | Journal Article |
| GeographicLocations | France |
| GeographicLocations_xml | – name: France |
| GrantInformation_xml | – fundername: Agence Nationale de la Recherche grantid: ANR grant RA-COVID-19 funderid: http://dx.doi.org/10.13039/501100001665 – fundername: Agence Nationale de la Recherche grantid: ANR grant RA-COVID-19 |
| GroupedDBID | --- 0R~ 29L 2WC 53G 5VS 6PF 7X7 88E 8FI 8FJ AAFWJ AAJSJ AASML AAWTL ABDBF ABUWG ACGFO ACGFS ACIHN ACIWK ACPRK ACUHS ADBBV ADUKV AEAQA AENEX AFKRA AFPKN AFRAH AHBYD AHMBA AHYZX ALMA_UNASSIGNED_HOLDINGS AMKLP AMTXH AOIJS BAPOH BAWUL BCNDV BENPR BFQNJ BMC BPHCQ BVXVI C6C CCPQU CS3 DIK DU5 E3Z EBD EBLON EBS ESX F5P FYUFA GROUPED_DOAJ GX1 HMCUK HYE IAO IHR INH INR ITC KQ8 M1P M48 M~E O5R O5S OK1 OVT P2P PGMZT PHGZM PHGZT PIMPY PJZUB PPXIY PQQKQ PROAC PSQYO PUEGO RBZ RNS ROL RPM RSV SBL SOJ TR2 TUS UKHRP WOQ WOW XSB ~8M AAYXX AFFHD CITATION ALIPV NPM 3V. 7T5 7XB 8FK AZQEC COVID DWQXO H94 K9. PKEHL PQEST PQUKI PRINS 7X8 1XC 2VQ 4.4 ADRAZ AHSBF EJD H13 IPNFZ RIG VOOES 5PM |
| ID | FETCH-LOGICAL-c642t-f8debf53e4c1e2aed98567838ac95963af1d3d22921bfe65d86f0ae601bd05b13 |
| IEDL.DBID | RSV |
| ISICitedReferencesCount | 13 |
| ISICitedReferencesURI | http://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=Summon&SrcAuth=ProQuest&DestLinkType=CitingArticles&DestApp=WOS_CPL&KeyUT=001181225800005&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D |
| ISSN | 1479-5876 |
| IngestDate | Fri Oct 03 12:53:34 EDT 2025 Tue Nov 04 02:05:49 EST 2025 Tue Dec 02 06:20:42 EST 2025 Fri Sep 05 07:05:15 EDT 2025 Sat Oct 18 23:49:34 EDT 2025 Tue Nov 11 11:06:31 EST 2025 Tue Nov 04 18:27:51 EST 2025 Mon Jul 21 06:03:33 EDT 2025 Tue Nov 18 21:07:03 EST 2025 Sat Nov 29 04:16:15 EST 2025 Sat Sep 06 07:28:43 EDT 2025 |
| IsDoiOpenAccess | true |
| IsOpenAccess | true |
| IsPeerReviewed | true |
| IsScholarly | true |
| Issue | 1 |
| Language | English |
| License | 2024. The Author(s). licence_http://creativecommons.org/publicdomain/zero/: http://creativecommons.org/publicdomain/zero Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data. |
| LinkModel | DirectLink |
| MergedId | FETCHMERGED-LOGICAL-c642t-f8debf53e4c1e2aed98567838ac95963af1d3d22921bfe65d86f0ae601bd05b13 |
| Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 14 content type line 23 |
| ORCID | 0000-0003-1112-4845 |
| OpenAccessLink | https://link.springer.com/10.1186/s12967-024-05044-7 |
| PMID | 38454482 |
| PQID | 2956883077 |
| PQPubID | 43076 |
| PageCount | 18 |
| ParticipantIDs | doaj_primary_oai_doaj_org_article_9b57d2df4cc14bfab42efddcb511b951 pubmedcentral_primary_oai_pubmedcentral_nih_gov_10919029 hal_primary_oai_HAL_hal_04567306v1 proquest_miscellaneous_2954770496 proquest_journals_2956883077 gale_infotracmisc_A785757343 gale_infotracacademiconefile_A785757343 pubmed_primary_38454482 crossref_citationtrail_10_1186_s12967_024_05044_7 crossref_primary_10_1186_s12967_024_05044_7 springer_journals_10_1186_s12967_024_05044_7 |
| PublicationCentury | 2000 |
| PublicationDate | 2024-03-07 |
| PublicationDateYYYYMMDD | 2024-03-07 |
| PublicationDate_xml | – month: 03 year: 2024 text: 2024-03-07 day: 07 |
| PublicationDecade | 2020 |
| PublicationPlace | London |
| PublicationPlace_xml | – name: London – name: England |
| PublicationTitle | Journal of translational medicine |
| PublicationTitleAbbrev | J Transl Med |
| PublicationTitleAlternate | J Transl Med |
| PublicationYear | 2024 |
| Publisher | BioMed Central BioMed Central Ltd Springer Nature B.V BMC |
| Publisher_xml | – name: BioMed Central – name: BioMed Central Ltd – name: Springer Nature B.V – name: BMC |
| References | C Karagiannidis (5044_CR6) 2020; 8 LE Cox (5044_CR25) 2020; 20 MM Lamers (5044_CR9) 2022; 20 M Saichi (5044_CR33) 2021; 23 M Napirei (5044_CR27) 2004; 380 M Singer (5044_CR46) 2016; 315 Q Wang (5044_CR17) 2021; 11 N Krinsky (5044_CR39) 2023; 21 P Bastard (5044_CR8) 2020; 370 A Duvignaud (5044_CR41) 2022; 28 R Zhou (5044_CR29) 2020; 53 WJ Wiersinga (5044_CR2) 2020; 324 H Englert (5044_CR36) 2023; 14 C Carmona-Rivera (5044_CR22) 2022; 7 IV Aramburu (5044_CR23) 2022; 55 D Matuozzo (5044_CR7) 2023; 15 J-L Vincent (5044_CR44) 1996; 22 A Bonaventura (5044_CR10) 2021; 21 A Kulkarni-Munje (5044_CR34) 2021; 9 F Mair (5044_CR49) 2021; 99 E Petersen (5044_CR1) 2020; 20 N Zhu (5044_CR3) 2020; 382 T Charlotte (5044_CR14) 2019; 39 J-RL Gall (5044_CR45) 1984; 12 C Thålin (5044_CR48) 2020; 18 M Severa (5044_CR35) 2021; 17 Acute Respiratory Distress Syndrome (5044_CR4) 2012 V Brinkmann (5044_CR12) 2004; 303 A Duvignaud (5044_CR42) 2020; 21 R Prével (5044_CR20) 2022; 13 O Roca (5044_CR18) 2019; 199 ZM Holliday (5044_CR38) 2021; 12 S Masuda (5044_CR21) 2016; 459 FP Veras (5044_CR40) 2023; 24 JD McFadyen (5044_CR15) 2020; 127 AG Laing (5044_CR32) 2020; 26 Cambridge Institute of Therapeutic Immunology and Infectious Disease-National Institute of Health Research (CITIID-NIHR) COVID-19 BioResource Collaboration (5044_CR19) 2021; 27 WHO (5044_CR43) 2022 V Sisirak (5044_CR28) 2016; 166 M Jiménez-Alcázar (5044_CR13) 2017; 358 M Napirei (5044_CR26) 2009; 276 S Sohrabipour (5044_CR24) 2021; 56 C Wu (5044_CR5) 2020; 180 Y Zuo (5044_CR16) 2021 JS Ayres (5044_CR37) 2020; 6 C Thålin (5044_CR47) 2017; 65 B Engelmann (5044_CR11) 2013; 13 B Peruzzi (5044_CR31) 2020; 161 Y Zhang (5044_CR50) 2013; 23 I Sánchez-Cerrillo (5044_CR30) 2020; 130 |
| References_xml | – volume: 12 start-page: 975 issue: 11 year: 1984 ident: 5044_CR45 publication-title: Crit Care Med doi: 10.1097/00003246-198411000-00012 – volume: 23 start-page: 743 year: 2013 ident: 5044_CR50 publication-title: Stat Comput doi: 10.1007/s11222-012-9343-7 – volume: 303 start-page: 1532 issue: 5663 year: 2004 ident: 5044_CR12 publication-title: Science doi: 10.1126/science.1092385 – volume: 459 start-page: 89 year: 2016 ident: 5044_CR21 publication-title: Clin Chim Acta doi: 10.1016/j.cca.2016.05.029 – volume: 18 start-page: 2732 issue: 10 year: 2020 ident: 5044_CR48 publication-title: J Thromb Haemost doi: 10.1111/jth.15003 – year: 2021 ident: 5044_CR16 publication-title: JCI Insight doi: 10.1172/jci.insight.150111 – volume: 55 start-page: 2436 issue: 12 year: 2022 ident: 5044_CR23 publication-title: Immunity doi: 10.1016/j.immuni.2022.11.007 – volume: 17 start-page: e1009878 issue: 9 year: 2021 ident: 5044_CR35 publication-title: PLoS Pathog doi: 10.1371/journal.ppat.1009878 – volume: 6 start-page: eabc1518 issue: 18 year: 2020 ident: 5044_CR37 publication-title: Sci Adv doi: 10.1126/sciadv.abc1518 – volume: 161 start-page: 345 issue: 4 year: 2020 ident: 5044_CR31 publication-title: Immunology doi: 10.1111/imm.13254 – volume: 26 start-page: 1623 issue: 10 year: 2020 ident: 5044_CR32 publication-title: Nat Med doi: 10.1038/s41591-020-1038-6 – volume-title: Clinical management of COVID-19: living guideline year: 2022 ident: 5044_CR43 – volume: 23 start-page: 538 issue: 5 year: 2021 ident: 5044_CR33 publication-title: Nat Cell Biol doi: 10.1038/s41556-021-00681-2 – volume: 21 start-page: 319 issue: 5 year: 2021 ident: 5044_CR10 publication-title: Nat Rev Immunol doi: 10.1038/s41577-021-00536-9 – volume: 382 start-page: 727 issue: 8 year: 2020 ident: 5044_CR3 publication-title: N Engl J Med doi: 10.1056/NEJMoa2001017 – volume: 22 start-page: 707 issue: 7 year: 1996 ident: 5044_CR44 publication-title: Intensive Care Med doi: 10.1007/BF01709751 – volume: 166 start-page: 88 issue: 1 year: 2016 ident: 5044_CR28 publication-title: Cell doi: 10.1016/j.cell.2016.05.034 – volume: 130 start-page: 6290 issue: 12 year: 2020 ident: 5044_CR30 publication-title: J Clin Investig doi: 10.1172/JCI140335 – volume: 24 start-page: 66 issue: 1 year: 2023 ident: 5044_CR40 publication-title: Respir Res doi: 10.1186/s12931-023-02336-2 – volume: 315 start-page: 801 issue: 8 year: 2016 ident: 5044_CR46 publication-title: JAMA doi: 10.1001/jama.2016.0287 – year: 2012 ident: 5044_CR4 publication-title: JAMA doi: 10.1001/jama.2012.5669 – volume: 27 start-page: 904 issue: 5 year: 2021 ident: 5044_CR19 publication-title: Nat Med doi: 10.1038/s41591-021-01329-2 – volume: 99 start-page: 231 issue: 3 year: 2021 ident: 5044_CR49 publication-title: Cytometry Pt A doi: 10.1002/cyto.a.24269 – volume: 199 start-page: 1368 issue: 11 year: 2019 ident: 5044_CR18 publication-title: Am J Respir Crit Care Med doi: 10.1164/rccm.201803-0589OC – volume: 15 start-page: 22 issue: 1 year: 2023 ident: 5044_CR7 publication-title: Genome Med doi: 10.1186/s13073-023-01173-8 – volume: 21 start-page: 846 issue: 1 year: 2020 ident: 5044_CR42 publication-title: Trials doi: 10.1186/s13063-020-04619-1 – volume: 20 start-page: e238 issue: 9 year: 2020 ident: 5044_CR1 publication-title: Lancet Infect Dis doi: 10.1016/S1473-3099(20)30484-9 – volume: 180 start-page: 934 issue: 7 year: 2020 ident: 5044_CR5 publication-title: JAMA Intern Med doi: 10.1001/jamainternmed.2020.0994 – volume: 7 start-page: e160332 issue: 16 year: 2022 ident: 5044_CR22 publication-title: JCI Insight doi: 10.1172/jci.insight.160332 – volume: 8 start-page: 853 issue: 9 year: 2020 ident: 5044_CR6 publication-title: Lancet Respir Med doi: 10.1016/S2213-2600(20)30316-7 – volume: 12 start-page: 714833 year: 2021 ident: 5044_CR38 publication-title: Front Immunol doi: 10.3389/fimmu.2021.714833 – volume: 20 start-page: 15 issue: 1 year: 2020 ident: 5044_CR25 publication-title: BMC Anesthesiol doi: 10.1186/s12871-019-0911-7 – volume: 13 start-page: 34 issue: 1 year: 2013 ident: 5044_CR11 publication-title: Nat Rev Immunol doi: 10.1038/nri3345 – volume: 20 start-page: 270 issue: 5 year: 2022 ident: 5044_CR9 publication-title: Nat Rev Microbiol doi: 10.1038/s41579-022-00713-0 – volume: 53 start-page: 864 issue: 4 year: 2020 ident: 5044_CR29 publication-title: Immunity doi: 10.1016/j.immuni.2020.07.026 – volume: 21 start-page: 2569 issue: 9 year: 2023 ident: 5044_CR39 publication-title: J Thromb Haemost doi: 10.1016/j.jtha.2023.02.033 – volume: 13 start-page: 851497 year: 2022 ident: 5044_CR20 publication-title: Front Immunol doi: 10.3389/fimmu.2022.851497 – volume: 11 start-page: e043790 issue: 10 year: 2021 ident: 5044_CR17 publication-title: BMJ Open doi: 10.1136/bmjopen-2020-043790 – volume: 39 start-page: 1724 issue: 9 year: 2019 ident: 5044_CR14 publication-title: Arterioscler Thromb Vasc Biol doi: 10.1161/ATVBAHA.119.312463 – volume: 14 start-page: 1181761 year: 2023 ident: 5044_CR36 publication-title: Front Immunol doi: 10.3389/fimmu.2023.1181761 – volume: 324 start-page: 782 issue: 8 year: 2020 ident: 5044_CR2 publication-title: JAMA doi: 10.1001/jama.2020.12839 – volume: 380 start-page: 929 issue: 3 year: 2004 ident: 5044_CR27 publication-title: Biochemical Journal doi: 10.1042/bj20040046 – volume: 9 start-page: 419 issue: 2 year: 2021 ident: 5044_CR34 publication-title: Immunity Inflam Dis doi: 10.1002/iid3.402 – volume: 127 start-page: 571 issue: 4 year: 2020 ident: 5044_CR15 publication-title: Circ Res doi: 10.1161/CIRCRESAHA.120.317447 – volume: 28 start-page: 1010 issue: 7 year: 2022 ident: 5044_CR41 publication-title: Clin Microbiol Infect doi: 10.1016/j.cmi.2022.02.031 – volume: 370 start-page: eabd4585 issue: 6515 year: 2020 ident: 5044_CR8 publication-title: Science doi: 10.1126/science.abd4585 – volume: 56 start-page: 975 issue: 6 year: 2021 ident: 5044_CR24 publication-title: Shock doi: 10.1097/SHK.0000000000001804 – volume: 276 start-page: 1059 issue: 4 year: 2009 ident: 5044_CR26 publication-title: FEBS J doi: 10.1111/j.1742-4658.2008.06849.x – volume: 65 start-page: 706 issue: 3 year: 2017 ident: 5044_CR47 publication-title: Immunol Res doi: 10.1007/s12026-017-8905-3 – volume: 358 start-page: 1202 issue: 6367 year: 2017 ident: 5044_CR13 publication-title: Science doi: 10.1126/science.aam8897 |
| SSID | ssj0024549 |
| Score | 2.4595144 |
| Snippet | Background
Thrombo-inflammation and neutrophil extracellular traps (NETs) are exacerbated in severe cases of COVID-19, potentially contributing to disease... Thrombo-inflammation and neutrophil extracellular traps (NETs) are exacerbated in severe cases of COVID-19, potentially contributing to disease exacerbation.... Background Thrombo-inflammation and neutrophil extracellular traps (NETs) are exacerbated in severe cases of COVID-19, potentially contributing to disease... BackgroundThrombo-inflammation and neutrophil extracellular traps (NETs) are exacerbated in severe cases of COVID-19, potentially contributing to disease... Background: Thrombo-inflammation and neutrophil extracellular traps (NETs) are exacerbated in severe cases of COVID-19, potentially contributing to disease... Abstract Background Thrombo-inflammation and neutrophil extracellular traps (NETs) are exacerbated in severe cases of COVID-19, potentially contributing to... |
| SourceID | doaj pubmedcentral hal proquest gale pubmed crossref springer |
| SourceType | Open Website Open Access Repository Aggregation Database Index Database Enrichment Source Publisher |
| StartPage | 246 |
| SubjectTerms | Adaptive immunology Analysis Antigens Biomarkers Biomedical and Life Sciences Biomedicine Care and treatment Clinical deterioration COVID-19 Cytotoxicity Dendritic cells Deoxyribonuclease Emerging diseases Hospital patients Hospitalization Human health and pathology Immunology ImmunoVirology and ImmunoOncology Infectious diseases Inflammation Innate immunity Intensive care Leukocytes (neutrophilic) Life Sciences Lymphocytes Medicine/Public Health Neutrophils Pandemics Patients Physiology Proteins Ratios RNA sequencing Sepsis Testing |
| SummonAdditionalLinks | – databaseName: Openly Available Collection - DOAJ dbid: DOA link: http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV1Lj9MwELZghRAXxJtAQQYhcYBoE8eO7WPZZbUrQeEAaG9W_FIrrdKqj5X498w4SSGsgAu3yHYTezwPTz3zDSGvwKeonZYhj40UOede5NY3NhfRFsJVtiosT8Um5Gymzs_1519KfWFMWAcP3BHuUFshPfORO1dyGxvLWYjeOwsnBatT8jSDU8_gTA0oe-D2DCkyqj7cgFUDhQDteSEKznM5MkMJrX-vk6_PMSTy6nnzatjkb3enySSd3CG3-7MknXZruEuuhfYeufmxvy2_T9ozkHVQaZ5aDGB0gfZRWbQNu-16uZovLigo53WDf99jPCqF5xXdJzTSpvXUI5xEV3mJ2u_0eAZ2b0MXLT369O3sOC817S95HpCvJ--_HJ3mfX2F3IHXsc2j8sFGUQXuysCa4LUSYLsq1TgtQDCbWPrKM6ZZaWOohVd1LJoALpz1hbBl9ZActMs2PCbUoScjY43g7jwqoWEAOEbSY54siHlGyoHcxvXg41gD48IkJ0TVptsiA1tk0hYZmZE3-9-sOuiNv45-h7u4H4mw2akBmMn0zGT-xUwZeY08YFC4kfhNn6MAi0SYLDOVWNBUVrzKyGQ0EoTSjbpfAheNJnM6_WCwDc_QoFbrS_jaZGAy02uOjWGYv6lA88KKXuy78fUYDdeG5S6N4VKCb1dn5FHHk_tPVQp4nyuWETXi1tFcxj3tYp5wxREjVhdMZ-TtwNg_5_Vnyj_5H5R_Sm6xJJ5VXsgJOdiud-EZueEut4vN-nkS7h8MpVFS priority: 102 providerName: Directory of Open Access Journals – databaseName: ProQuest Central dbid: BENPR link: http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV1Lj9MwELbYLkJceC8ECjIIiQNYm4cdOyfUfWlXgrJCgPZmxS9aaZWWPlbi3zOTuq3Cir1wi2wnseOZzzPx-BtC3oJPUdpKehZqKRjnTjDjasNEMKmwhSlSw9tkE3I4VBcX1Xn84TaPYZVrTGyB2k0s_iPfz_FcmwKJlB-nvxhmjcLd1ZhCY4fsIlMZ75Hdg-Ph-dct2x64P-ujMqrcn8PqBsAA5SwVKedMdpajlrV_g807IwyNvG53Xg-f_GsPtV2aTu7_76AekHvRKKWDlRQ9JLd884jc-Ry33R-T5gxAA7DRUYORkNbTGN5FG79czCbT0fiSAsrPatwHwMBWCtdTujkZSevGUYe8FKsUTtT8pkdDWEDndNzQwy8_zo5YVtG4W_SEfD85_nZ4ymKiBmbBfVmwoJw3QRSe28zntXeVErAIFqq2lQANr0PmCpfnVZ6Z4EvhVBnS2oMvaFwqTFbskV4zafwzQi26RDKUyBLPgxIVNAAPSzo8cAt4kZBsPV_aRhZzTKZxqVtvRpV6Ncca5li3c6xlQt5v7pmuODxubH2AYrBpifzbbcFk9lNHddaVEdLlLnBrM25CbXjug3PWgP1qwGhNyDsUIo0ogR-_jocdYJDIt6UHEjOjyoIXCel3WoJ22071GxDDTmdOB580lqExDvhcXsHb-mvx0hGC5norWwl5vanGx2NYXeMny7YNlxKcxDIhT1dCvXlVoUB5uMoTojri3ulLt6YZj1qCciSbrdK8SsiHtWZs-_XvL__85mG8IHfzVnMLlso-6S1mS_-S3LZXi_F89ipq_h83gl7_ priority: 102 providerName: ProQuest |
| Title | Impaired balance between neutrophil extracellular trap formation and degradation by DNases in COVID-19 disease |
| URI | https://link.springer.com/article/10.1186/s12967-024-05044-7 https://www.ncbi.nlm.nih.gov/pubmed/38454482 https://www.proquest.com/docview/2956883077 https://www.proquest.com/docview/2954770496 https://hal.science/hal-04567306 https://pubmed.ncbi.nlm.nih.gov/PMC10919029 https://doaj.org/article/9b57d2df4cc14bfab42efddcb511b951 |
| Volume | 22 |
| WOSCitedRecordID | wos001181225800005&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D |
| hasFullText | 1 |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| journalDatabaseRights | – providerCode: PRVADU databaseName: Open Access: BioMedCentral Open Access Titles customDbUrl: eissn: 1479-5876 dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0024549 issn: 1479-5876 databaseCode: RBZ dateStart: 20030101 isFulltext: true titleUrlDefault: https://www.biomedcentral.com/search/ providerName: BioMedCentral – providerCode: PRVAON databaseName: DOAJ Directory of Open Access Journals customDbUrl: eissn: 1479-5876 dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0024549 issn: 1479-5876 databaseCode: DOA dateStart: 20030101 isFulltext: true titleUrlDefault: https://www.doaj.org/ providerName: Directory of Open Access Journals – providerCode: PRVHPJ databaseName: ROAD: Directory of Open Access Scholarly Resources customDbUrl: eissn: 1479-5876 dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0024549 issn: 1479-5876 databaseCode: M~E dateStart: 20030101 isFulltext: true titleUrlDefault: https://road.issn.org providerName: ISSN International Centre – providerCode: PRVPQU databaseName: Health & Medical Collection customDbUrl: eissn: 1479-5876 dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0024549 issn: 1479-5876 databaseCode: 7X7 dateStart: 20090101 isFulltext: true titleUrlDefault: https://search.proquest.com/healthcomplete providerName: ProQuest – providerCode: PRVPQU databaseName: ProQuest Central customDbUrl: eissn: 1479-5876 dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0024549 issn: 1479-5876 databaseCode: BENPR dateStart: 20090101 isFulltext: true titleUrlDefault: https://www.proquest.com/central providerName: ProQuest – providerCode: PRVPQU databaseName: Publicly Available Content Database (Proquest) customDbUrl: eissn: 1479-5876 dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0024549 issn: 1479-5876 databaseCode: PIMPY dateStart: 20090101 isFulltext: true titleUrlDefault: http://search.proquest.com/publiccontent providerName: ProQuest – providerCode: PRVAVX databaseName: Springer Nature customDbUrl: eissn: 1479-5876 dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0024549 issn: 1479-5876 databaseCode: RSV dateStart: 20030601 isFulltext: true titleUrlDefault: https://link.springer.com/search?facet-content-type=%22Journal%22 providerName: Springer Nature |
| link | http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1Zj9MwELbYXYR44T4CpTIIiQewNocdO4_dS1uJLdUCq_JkxRettEqrHivx7xm7SVZhAQleoiaeNLYz881MPDNG6C34FLkuuCWu5IxQahhRplSEORUznaksVjRsNsFHIzGZFOM6KWzVRLs3S5IBqYNYi3x_BZoJhBp0ColZTCnhO2gP1J3w4nj--eK6wh64PE16zG_v66igUKm_xeOdqQ-HvGlr3gyZ_GXdNKijk_v_N5AH6F5tfuLBll8eolu2eoTunNUL7I9RNQR4ABQ0WPmYR21xHciFK7tZL-eL6ewSA54vS__F34ewYvi9wG0OJC4rg42vQLHdrAmrH_hoBKpyhWcVPvx0MTwiSYHrdaEn6OvJ8ZfDU1JvyUA0OCpr4oSxyrHMUp3YtLSmEAzUXSZKXTCQ5dIlJjNpWqSJcjZnRuQuLi14fcrETCXZU7RbzSv7HGHtnR_ucl8PnjrBCiAAX4obn1oLyBChpHlLUtf1yv22GZcy-C0il9uJlDCRMkyk5BF6396z2Fbr-Cv1gX_5LaWvtB0uzJffZS24slCMm9Q4qnVClSsVTa0zRiuwVBWYpxF651lHejzwk1_WaQ0wSF9ZSw643wOVZzSLUK9DCXKsO81vgPk6nTkdfJT-mje7AYnzK3har-FNWYPNSqY-5VMAWMOIXrfN_u99AF1l55tAQzkHdzCP0LMtK7ePygSIDBVphESHyTt96bZUs2koRe7LyhZxWkToQ8Pr1_3688y_-Dfyl-huGsQlIzHvod31cmNfodv6aj1bLftoh094OIo-2js4Ho3P--HTCpyNh2fjb_2ADz8BkvdZwQ |
| linkProvider | Springer Nature |
| linkToHtml | http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMw1V1Lb9NAEB71gYAL74ehwIJAHMCqH2vv-oBQaakSNQk5tKicFu_DNFLlhCQt6p_iNzLj2KlMRW89cIt2N_bu5ptvZ7LzAHiNNkVqMuH8IheJz7lNfG1z7SeFDhIT6zjQvCo2IQYDeXiYDVfgdxMLQ26VDSdWRG3Hhv4j34work0iIsXHyU-fqkbR7WpTQmMBiz139gtNttmH7g7-vm-iaPfz_nbHr6sK-AZ17blfSOt0kcSOm9BFubOZTJCxY5mbLEE45kVoYxtFWRTqwqWJlWkR5A4NF22DRIcxPncV1jmCXa7B-rDbH347z-6H5lYTmiPTzRmepkhE2O4HScC5L1rHX1UlYHkWrB6RK-ZFPfeiu-Zfd7bVUbh7-3_bxDtwq1a62dZCSu7CiivvwfV-7VZwH8oukiJyv2WaPD2NY7X7GivdyXw6nhyNjhmeYtOc7jnIcZfh5wlbRn6yvLTMUt6NRYkqps_YzgAVhBkblWz7y9fujh9mrL4NewAHV7Lah7BWjkv3GJghk08UKWXB54VMMhyAFqSwFFCMfOhB2OBDmTpLOxULOVaVtSZTtcCUQkypClNKePBu-Z3JIkfJpaM_EeyWIym_eNUwnv5QNV2pTCfCRrbgxoRcF7nmkSusNRr1c41KuQdvCbSKWJA2P6-DOXCRlE9MbQmq_CpiHnuw0RqJ7GVa3a8Q9q3JdLZ6itrI2MDzJz3Ft200cFY1xc7UOZY9eLnspseT22DpxifVGC4EGsGpB48WQrR8VSxRWLmMPJAt8WrNpd1Tjo6qBOyUTDcLosyD940kns_r3zv_5PJlvIAbnf1-T_W6g72ncDOqWCP2A7EBa_PpiXsG18zpfDSbPq9Zh8H3q5bRPxbhvZY |
| linkToPdf | http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV1bb9MwFLbYQBMv3C-BAgYh8cCi5WLHzmNZqVYxyiRg2psV32ilKa3SdhL_nnOSNCMMkBBvUXyS2M65yud8h5DXEFNkJhcu9IXgIWOWh9oWOuReR9ykOo00q5tNiOlUnp3lJz9V8dfZ7tsjyaamAVGayvXB0vpGxGV2sAIrBQIO9iWMeMRYKHbIdYZNgzBe_3x6ibYH4c-2VOa3z_XMUY3a3-nmnRmmRl71O6-mT_5yhlqbpvHt_1_UHXKrdUvpsOGju-SaK--RvY_twft9Uk5AbYB2tFRjLqRxtE3woqXbrKvFcjY_p6DnqwJPAjC1lcL1kna1kbQoLbWITNE0caL6Ox1NwYSu6Lykh59OJ6Mwzml7XvSAfB2__3J4FLatGkIDAcw69NI67XnqmIldUjibSw5mMJWFyTnIeOFjm9okyZNYe5dxKzMfFQ6iQW0jruP0IdktF6V7TKjBoEj4DHHimZc8BwKIsYTFklvQGAGJt39MmRbHHNtpnKs6npGZajZSwUaqeiOVCMjb7pllg-LxV-p3yAgdJSJw1zcW1TfVCrTKNRc2sZ4ZEzPtC80S5601GjxYDW5rQN4gGynUE7j5RVvuAItExC01FNgbVaQsDcigRwnybXrDr4ARe5M5Gh4rvIfuOGjo7AK-NtjyqWqV0EolWAoqQYnDil52w_h6TKwr3WJT0zAhIEzMAvKoYevuU6kE8WEyCYjsMXxvLv2Rcj6rIcoRbjaPkjwg-1u-v5zXn3f-yb-RvyB7J6OxOp5MPzwlN5NactIwEgOyu6427hm5YS7W81X1vFYKPwC_a195 |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Impaired+balance+between+neutrophil+extracellular+trap+formation+and+degradation+by+DNases+in+COVID-19+disease&rft.jtitle=Journal+of+translational+medicine&rft.au=Garcia%2C+Geoffrey&rft.au=Labrouche-Colomer%2C+Sylvie&rft.au=Duvignaud%2C+Alexandre&rft.au=Clequin%2C+Etienne&rft.date=2024-03-07&rft.pub=BioMed+Central&rft.eissn=1479-5876&rft.volume=22&rft.issue=1&rft_id=info:doi/10.1186%2Fs12967-024-05044-7&rft.externalDocID=10_1186_s12967_024_05044_7 |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1479-5876&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1479-5876&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1479-5876&client=summon |